High‐throughput screening and biological display technology: Applications in molecular imaging

Luo, Renli; Liu, Hongguang; Cheng, Zhen

doi:10.1002/ird3.11

Cited by 3 publications

(2 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomedical optical imaging has emerged as a powerful tool to be used in pre-clinical research, clinical diagnosis, and intraoperative detection of tumors. − Several HER2-targeted fluorescent probes that emit light in the visible (400–700 nm) and near-infrared window one region [near-infrared window one region I (NIR-I), 700–1000 nm] have been developed for imaging HER2-positive tumors and show promise for cancer detection . Recently, near-infrared window II region (NIR-II, 1000–1700 nm) imaging has demonstrated many advantages such as minimal autofluorescence, low light scattering, increased imaging sensitivity, and tissue penetration depth over the traditional visible and NIR-I imaging techniques, and it provides a promising, non-invasive, and real-time imaging technique for monitoring diseases in vivo .…”

Section: Introductionmentioning

confidence: 99%

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Cao

Lai

et al. 2023

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) may serve as a valid target for diagnosis of cancer. The probes with capability for near-infrared window one region II (NIR-II) and positron emission tomography (PET) dual-modal imaging are highly desired for HER2-positive tumor detection. Herein, three HER2-targeted peptides were designed and further modified with indocyanine green (ICG) and 2,2′,2″,2″-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), which were used for NIR-II imaging and complexation with 68Ga for PET. Among the resulted probes (DOTA-ZC01-ICG, DOTA-KSP-ICG, and DOTA-ZC02-ICG), NIR-II imaging revealed that DOTA-ZC02-ICG had the best tumor imaging performance in SKOV3 tumor-bearing mice. The highest T/N ratio (5.4) was achieved at 4 h post-injection. Furthermore, DOTA-ZC02-ICG was radiolabeled with 68Ga to generate [68Ga]-DOTA-ZC02-ICG for PET, and it clearly delineated at 0.5, 1, and 2 h post-injection. The tumor uptake reached 1.9 %ID/g at 0.5 h, and the tumor uptakes were significantly inhibited in the blocking study (p < 0.05). Overall, it provides a promising technique for tumor dual-modal imaging and a new molecular scaffold for developing HER2-targeted theranostic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Cao

Lai

et al. 2023

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…By providing noninvasive, real-time, dynamic, and quantitative transdimensional visualization and monitoring of sub-cells, cells, tissues, organs, and organisms, molecular imaging has facilitated drug discovery and development [27][28][29], which are characterized by long research and development periods, high costs, and low success rates. One of the most important steps of drug discovery and development is the selection and validation of drug targets.…”

Section: Introductionmentioning

confidence: 99%

Harnessing the power of molecular imaging for drug discovery and development

Luo,

Tan,

Zhao

et al. 2023

iRADIOLOGY

View full text Add to dashboard Cite

Non‐invasive, real‐time, dynamic, and quantitative molecular imaging has been developed to facilitate disease diagnosis, drug development, and pathological analysis at the molecular level. Qualitative and quantitative analysis and imaging of physiological processes at the molecular level can be achieved with advanced molecular imaging by employing imaging contrast agents in combination with traditional imaging modalities, such as optical imaging, ultrasound imaging, magnetic resonance imaging, single‐photon emission computed tomography, and positron emission tomography. With the aid of molecular imaging, absorption, distribution, metabolism, excretion, and other processes of drugs in various animals can be monitored quantitatively, and in vivo pharmacokinetics and pharmacodynamics can be simulated before clinical trials, which significantly shorten the period for drug development and reduce the number of animals participating in various tests. Here, the role of molecular imaging in drug target validation, drug screening, drug sensitivity analysis, pharmacokinetics research, drug efficacy evaluation, and other processes of chemical and biological drug research and development is summarized. Molecular imaging has become a powerful and effective tool in the research and development of various drugs for the treatment of a variety of diseases. Advanced molecular imaging can provide important support for disease and drug research, which will accelerate drug discovery and development.

show abstract

The development of logic gate-based fluorescent probes that respond to intracellular hydrogen peroxide and pH in tandem

Han,

Liu,

Zhang

et al. 2024

Talanta

View full text Add to dashboard Cite

High‐throughput screening and biological display technology: Applications in molecular imaging

Cited by 3 publications

References 109 publications

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Harnessing the power of molecular imaging for drug discovery and development

The development of logic gate-based fluorescent probes that respond to intracellular hydrogen peroxide and pH in tandem

Contact Info

Product

Resources

About